external image Affymetrix_color_logo_jpg.jpg

General Information

[1] [2] [3]
Company Name
Year founded
Santa Clara, California ; High Wymcombe, UK ; Tokyo, Japan ; Shangai, China
Number of Locations
Key People
Stephen P. A. Fodor, PhD
$327 Million /2009
Operating Income
($33 Million) /2009
Net Income
($24Million) /2009

Affymetrix is a biotechnology company working on the DNA microarray area, mainly known for the production of GeneChip® technology.
In the late 80’s a group led by Stephen P. A. Fodor, PhD developed a technology able to manufacture DNA microarrays combining chemical synthesis and photo lithography and submitted a patent for the GeneChip. In 1991 Fodor’s group started working as a division of Affymax N.V. and in 1992 Fodor and Peter G. Shultz cofounded Affymetrix. The company’s first product, an HIV genotyping GeneChip, was released in 1994. The company went public in 1996 and, today, is represented in NASDAQ biotechnology index under the name AFFX. Affymetrix managed to expand itself all over the 5 continents, currently being present in 13 locations.
Affymetrix holds a market value of about $300 million/year mostly due to its large patent portfolio on DNA microarray technologies and some aggressive market strategies. The company possesses about 80 patents on areas like arrays, array analysis, chemical detection and chemical synthesis. Affymetrix is also owner of 6 trademarks and a large variety of computer software. There are about 21 500 articles published either by Affymetrix’s scientists or on Affymetrix related technologies.
The company policies are known for some aggressiveness on the market. All over the years Affymetrix have acquired 6 companies in areas like bioinformatics and reagent production in order to expand its business.



  • Late 80's - A group led by Stephen Fodor,PhD developed the technology for GeneChip® combining techniques of chemical synthesis of oligonucleotides with photo-lithographic techniques.

  • 1991 - Fodor's group started working as a division of Affymax N. V. and submitted several patents for their technologies.

  • 1992 - Affymetrix started to work independently with headquarters in Santa Clara, California. The company Founders were Stephen P.A. Fodor and Peter G. Shultz.

  • 1994 - The first Affymetrix's product, an HIV genotyping GeneChip® was introduced. This product started Affymetrix on the sales of systems for research.
In June the patent for "Method and apparatus for measuring binding affinity" was granted as USPN 5324633.

  • 1995 - In August the patent "Array of oligonucleotides on a solid substrate" was issued under the number USPN 5445934

  • 1996 - In June the initial public offering was completed. The company started to be present in the stock-market under the name AFFX.

  • 2000 - Affymetrix acquired Genetic MicroSystems, a privately held Massachusetts instrumentation company specializing in DNA array technology, in February. In October, Affymetrix acquired Neomorphic, a privately held computational genomics company.

  • 2005 - Affymetrix acquired ParAllele BioScience, a privately held provider of highly-scalable technology for comprehensive genetic studies, in October.

  • 2007 - Affymetrix acquired USB Corporation, a privately held Cleveland, Ohio-based company that provides an extensive line of molecular biology and biochemical reagent products, in December. The acquisition included Anatrace Inc., a wholly-owned subsidiary that provides membrane protein extraction and purification products.

  • 2008 - Affymetrix acquired True Materials Inc., a privately held San Francisco-based company that has developed a technology capable of multiplexing up to 10,000 markers, in July. In November,, Affymetrix acquired Panomics Inc., a privately held Fremont, Calif.-based company that offers a powerful suite of assay products for a wide variety of low to mid-plex genetic, protein and cellular analysis applications.


The most well known products from Affymetrix are the DNA microarrays sold under the name GeneChip®. Although, today Affymetrix possesses several brands selling products in some parallel areas.
external image 2009-11-affy-brand-logo.jpg
With more than 1,860 installed systems worldwide and nearly 20,000 peer-reviewed publications, the GeneChip® System is the platform of choice for analyzing complex genetic information. Researchers use the data generated by our products to explore the relationship between genes and diseases, find and develop new drugs, and develop diagnostic tests.
Affymetrix microarray solutions include all necessary components for a microarray experiment, from arrays and reagents to instruments and software.
external image 2009-11-anatrace-brand-logo.jpg
Anatrace, now part of Affymetrix, is a recognized leader in detergents and lipids for membrane protein studies. Anatrace offers a wide variety of unique, high-purity detergents, including lipid-like Fos-Choline® detergents, CYMAL® detergents, and general glucosides and maltosides.
external image 2009-11-usb-brand-logo.jpg
USB, now part of Affymetrix, provides high-quality molecular biology reagents to life science researchers. The USB line includes well-known products such as ExoSAP-IT® for PCR cleanup, HotStart-IT® real-time and endpoint PCR solutions, Tested User Friendly™ molecular biology enzymes, PrepEase® purification kits, Ultrapure Biochemicals, and a wide variety of convenience reagents.
external image 2009-11-panomics-brand-logo.jpg
The QuantiGene® product line is based on branched DNA (bDNA) technology, which delivers quantitative genetic analysis of unparalleled quality. The workflow eliminates the need for RNA or DNA isolation, PCR, and reverse transcription. QuantiGene products can be configured in single- and multiplex formats and are compatible with many sample types, from animal or plant tissues, whole blood, formalin-fixed, paraffin-embedded (FFPE) sections, and cultured cells.
QuantiGene ViewRNA
The QuantiGene ViewRNA Assay is a novel mRNA in situ hybridization solution that offers single-copy mRNA sensitivity in single cells in a multiplex assay format.
Based on patent-pending probe set design and proprietary signal amplification methodology, this technology enables transcriptional profiling of individual cells within a population. The QuantiGene ViewRNA Assay can be used in a wide range of research areas, including biomarker validation and in vitro/in vivo RNAi delivery and knockdown. In addition, the automation-friendly, simple workflow is suitable for high-throughput applications such as phenotypic or reporter gene screening.
Procarta Assays enable simultaneous monitoring of inter- and intracellular protein signaling pathways in a 96-well plate format. The Procarta line includes a family of products that measure protein expression and monitor protein modification/activation states in diverse matrices.
Procarta Assays use xMAP® technology (mutli-analyte profiling beads) to enable the detection and quantitation of multiple protein targets simultaneously. Procarta Assay Kits are compatible with all currently available Luminex® and Luminex-based instruments.

Executive Staff


external image KevinKing_FINAL_07_02_09.JPG

Kevin M. King

Affymetrix President and CEO
external image fodor.jpg

Stephen P.A. Fodor, Ph.D.
Executive Chairman
external image AndyLast_FINAL_04_01_10.JPG

Andrew J. Last, Ph.D.
Executive Vice President and Chief Commercial Officer
external image RickRunkel_FINAL_07_02_09.JPG

Rick Runkel
Executive Vice President, General Counsel and Secretary

Financial Information.

Selected Financial data from 2009 Annual Report

The report refers the net loss as Financial Restructuring of the company. It is possible to observe an incremental growth on the total revenue from 2005 to 2008 as result of that restructuring plan. 2009 reported low revenue due the the economical crisis.

João Trabuco 68667 MBiotec

  1. bioinformatics
  2. biopharmaceutical
  3. company
  4. genetic tests
  5. monoclonal antibodies
  6. nanobiotechnology
  7. penicillin; antibiotics
  8. pharmaceutical
  9. poland
  10. portugal
  11. product
  12. technology
  13. tool
  14. vaccine

  1. ^
  2. ^ Affymetrix 2009 annual report
  3. ^
  4. ^
  5. ^
  6. ^
  7. ^ Affymetrix 2009 annual report